Novo Nordisk A/S's Moses: "We Are Open to Sharing" Data With the American Diabetes Association

Published: Jun 28, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Two weeks ago, the NIH ran a workshop to examine the safety of several widely used diabetes drugs called GLP-1 inhibitors and whether a definitive link can be established to acute pancreatitis and pancreatic cancer, which were the subject of recent studies that generated considerable controversy. The outcome was inconclusive, but the FDA may want further studies. Meanwhile, the American Diabetes Association called for drugmakers that sell these meds to release patient-level data that can be used for an independent review (back stories here, here and here). To what extent the drugmakers - Merck, Bristol-Myers Squibb, AstraZeneca, Eli Lilly, Novo Nordisk and Boehringer Ingelheim – will comply remains to be seen. With the exception of GlaxoSmithKline, the pharmaceutical industry has resisted releasing such data over concerns that proprietary information will be compromised.

Help employers find you! Check out all the jobs and post your resume.

Back to news